

ANTEO TECHNOLOGIES ANNOUNCES VERIFICATION STUDY WITH COOK MEDICAL AUSTRALIA

07 March 2017

- **Anteo enters into verification study following completion of the feasibility investigation**
- **Anteo expands re-formulation activities of its nano surface chemistry using Generally Regarded as Safe (GRAS) materials and incorporation of specific functional modalities**
- **Solidifies the strategy underpinning the *in-vivo* medical devices sector**

Anteo Diagnostics Limited (ASX: ADO) advises that the previously disclosed feasibility study undertaken with Cook Medical Australia has been completed. The study outcomes were compelling and are now the subject of a fully funded verification study due to commence this quarter. Anteo is pleased with the progress that has been made to date and welcomes the opportunity to continue to work with Cook Medical in applying novel technologies to products that will ultimately lead to the improvement of health outcomes for patients.

For Anteo, this marks an important milestone in the commercialisation approach taken to fast track the deployment of the technology to *in-vivo* Medical Devices applications. In response to the lengthier expected timelines for products to reach the market, Anteo elected to concurrently drive a number of critical activities as follows;

- undertake application specific research & development;
- chemistry refinement; and
- expansion of the intellectual property portfolio.

Anteo has embarked on an extensive internal program to re-formulate its chemistry with starting materials known to be safe for human use and compatible with *in-vivo* applications. Together with the previously announced patent filings, Anteo has rapidly increased the technology readiness within the *in-vivo* Medical Devices segment allowing for partnering earlier than would otherwise have occurred.

Anteo Group CEO Dr Jef Vangenechten said, “The Company’s innovation arm has made significant progress in furthering work with partners on a number of medical device applications including implantable devices, *in-vivo* use medical devices and medical imaging.

“The collaboration with Cook Medical Australia has been constructive to date and we welcome the opportunity to continue with the program of works planned”, said Dr Vangenechten.

Barry Thomas, Director Cook Medical - Asia Pacific, says this is an important milestone as the technology was the first approved concept identified through the Asia-Pacific New Technologies Team (ANTT), which was formed to discover new technologies that can be commercialised by Cook Medical globally.

“The success of the feasibility study highlights the importance of supporting local research and development initiatives and to help them advance their technology—particularly if there’s an opportunity to improve patient health outcomes,” said Mr Thomas.

Anteo has a vision to provide functional nanometre-thin coatings and binders across multiple industries and applications. In this area we focus on improving the performance and utility of Medical Devices, where there are challenges in surface chemistries, to achieve better outcomes for our partners and most importantly better and safer outcomes for patients. The market for medical coatings alone is projected to reach \$13.23 billion by 2019*.

* *Markets & Markets*

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

About Cook Medical

Founded in 1963, Cook Medical pioneered many of the medical devices now commonly used to perform minimally invasive medical procedures. Today, the company integrates medical devices, drugs and biologic grafts to enhance patient safety and improve clinical outcomes. Since its inception, Cook has operated as a family-held private corporation.

For more information, visit www.cookmedical.com or

<https://www.facebook.com/CookMedicalAUS>

Follow Cook Medical on Twitter @CookMedicalAPAC @CookAPACMD